SCHEMBL730837

SCHEMBL730837

COC(=O)c1cc(C(N)=O)cc(N2CCCC2)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.50
NPC1 O15118 3/20 0.50
RAB9A P51151 3/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50
ALDH1A1 P00352 8/20 0.43
KMT2A Q03164 5/20 0.42
MEN1 O00255 4/20 0.42
USP2 O75604 1/20 0.42
CHRNB2 P17787 1/20 0.42
CHRNA4 P43681 1/20 0.42
POLB P06746 2/20 0.41
GAA P10253 3/20 0.41
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA7 P43166 1/20 0.41
CA9 Q16790 1/20 0.41
CA14 Q9ULX7 1/20 0.41
HPGD P15428 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL730949 0.92 KDM4E (0.53) KDM4ENPC1RAB9ASMN1; SMN2NPSR1
SCHEMBL3510581 0.90 KDM4E (0.55) KDM4ENPC1RAB9ASMN1; SMN2NPSR1
SCHEMBL14150012 0.88 KDM4E (0.48) KDM4ENPC1RAB9ASMN1; SMN2NPSR1
SCHEMBL4727575 0.87 MRGPRX4 (0.49) NPC1RAB9ASMN1; SMN2ALDH1A1KMT2A
SCHEMBL730950 0.86 ALDH1A1 (0.53) KDM4ENPC1RAB9ASMN1; SMN2NPSR1
SCHEMBL2276958 0.81 NOTUM (0.49) KDM4ENPC1RAB9ASMN1; SMN2NPSR1
SCHEMBL10889230 0.81 CA1 (0.58) KDM4EALDH1A1USP2POLBGAA
Hydrochloric Acid SCHEMBL17113220 0.80 LOXL2 (0.49) KDM4ENPC1RAB9ASMN1; SMN2NPSR1
SCHEMBL21817920 0.79 KDM4E (0.45) KDM4ENPC1RAB9ASMN1; SMN2NPSR1
SCHEMBL475555 0.78 MRGPRX4 (0.54) KDM4ENPC1RAB9ASMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2120569-B1 SPIROCHROMANON DERIVATIVES MERCK SHARP & DOHME (US) 2013-08-14 EP disclosed
EP-2120569-B1 SPIROCHROMANON DERIVATIVES MERCK SHARP & DOHME (US) 2013-08-14 EP disclosed
US-8138197-B2 Spirochromanon derivatives MSD K.K. (JP) 2012-03-20 US disclosed
US-8138197-B2 Spirochromanon derivatives MSD K.K. (JP) 2012-03-20 US disclosed
EP-2120569-A2 SPIROCHROMANON DERIVATIVES Merck & Co., Inc. (US) 2009-11-25 EP disclosed
US-20090270436-A1 SPIROCHROMANON DERIVATIVES MERCK SHARP & DOHME LLC 2009-10-29 US disclosed
US-20090270436-A1 SPIROCHROMANON DERIVATIVES MERCK SHARP & DOHME LLC 2009-10-29 US disclosed
WO-2008088692-A2 SPIROCHROMANON DERIVATIVES MERCK & CO., INC. (US) 2008-07-24 WO disclosed
WO-2008088692-A2 SPIROCHROMANON DERIVATIVES MERCK & CO., INC. (US) 2008-07-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270436-A1 SPIROCHROMANON DERIVATIVES AKR1C3, CBR3, AKR1C4 KDM4E 3445/4885NPC1 2438/4885RAB9A 2465/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.